iti-1284
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 11, 2024 (NCT06299410)
Timeline
Indications
Mechanism of action
- Dopamine D2 receptorPARTIAL AGONIST
DRD2 partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06786286 | Phase 1 | Jan 28, 2025 | Intra-Cellular Therapies |
| NCT06701903 | Phase 2 | Nov 30, 2024 | Intra-Cellular Therapies |
| NCT06651567 | Phase 2 | Oct 31, 2024 | Intra-Cellular Therapies |
| NCT06540833 | Phase 2 | Aug 15, 2024 | Intra-Cellular Therapies |
| NCT06480383 | Phase 2 | Aug 5, 2024 | Intra-Cellular Therapies |
| NCT06299410 | Phase 1 | Apr 11, 2024 | Intra-Cellular Therapies |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intra-Cellular Therapies | For profit | 6 | 6 | 2 | 2024 |
1 organizations
Page 1 / 1